San Francisco—Hims & Hers Health, Inc. (NYSE:HIMS) Chief Financial Officer Okupe Oluyemi recently made significant transactions involving the company's Class A Common Stock. According to a recent SEC filing, Oluyemi sold shares totaling approximately $5.48 million on October 14, 2024. The shares were sold at prices ranging from $19.9494 to $21.0699 per share.
Additionally, Oluyemi executed stock option exercises, acquiring shares at prices between $5.01 and $11.53. These transactions were conducted under a Rule 10b5-1 trading plan adopted earlier this year on May 31, 2024. Following these transactions, Oluyemi holds 145,763 shares directly.
In other recent news, Hims & Hers Health, Inc. reported a remarkable 52% year-over-year revenue increase in Q2 2024, reaching $316 million, and an adjusted EBITDA of $39 million. The company also expanded its market reach through the acquisition of MedisourceRx, issuing 976,341 Class A common shares to Nivagen Pharmaceuticals, Inc. In the wake of these developments, BofA Securities raised its price target for Hims & Hers from $20.00 to $23.00, maintaining a Buy rating. This adjustment followed the FDA's announcement to reassess the availability of tirzepatide, a drug previously on the agency's shortage list. Truist Securities and Citi maintained their hold and neutral ratings, respectively, while Canaccord Genuity sustained its Buy rating, citing the potential of the company's compounded GLP-1 medications amid rising obesity trends. These are recent developments that continue to shape the trajectory of Hims & Hers.
InvestingPro Insights
The recent stock transactions by Hims & Hers Health's CFO Okupe Oluyemi align with several key insights from InvestingPro. The company's stock has shown remarkable performance, with InvestingPro data indicating a 263.06% price total return over the past year and a 79.67% return in the last six months. This strong momentum is reflected in an InvestingPro Tip noting a "significant return over the last week," with the stock up 21.73% in just seven days.
Despite the impressive stock performance, investors should be aware that Hims & Hers is currently trading at a high valuation. The company's P/E ratio stands at 268.24, and an InvestingPro Tip cautions that it is "trading at a high earnings multiple." This elevated valuation comes as the company experiences robust growth, with revenue increasing by 50.15% in the last twelve months to $1.07 billion.
Interestingly, while the CFO has sold shares, another InvestingPro Tip reveals that "management has been aggressively buying back shares," suggesting confidence in the company's future prospects. For investors seeking a more comprehensive analysis, InvestingPro offers 16 additional tips for Hims & Hers Health, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.